Article info
PDFResearch ethics
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib
- Correspondence to: M J James Rheumatology Unit, Royal Adelaide Hospital, North Terrace, Adelaide, SA, Australia 5000; michael.jamesadelaide.edu.au
Citation
Applying a research ethics committee approach to a medical practice controversy: the case of the selective COX-2 inhibitor rofecoxib
Publication history
- Accepted November 6, 2003
- Revised November 2, 2003
- First published April 13, 2004.
Online issue publication
April 13, 2004
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2004 by the Journal of Medical Ethics
Other content recommended for you
- The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs
- Role of the selective cyclo-oxygenase-2 (COX-2) inhibitors in children
- Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials
- The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction
- Variability in the Response to Cyclooxygenase Inhibitors
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis
- COX-2-dependent and independent effects of COX-2 inhibitors and NSAIDs on proatherogenic changes in human monocytes/macrophages
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations
- Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis